NgospelMedia.net is The No. 1 International Urban Gospel Media Website, The Largest Repository of Your Favorite Gospel Entertainment Website, Worldwide, Nigeria. We Published Latest Nigerian and Foreign Gospel Music Downloads, Videos; Lyrics, Artiste Biography, Daily Devotionals. NgospelMedia is mainly a Christian Website, as the Domain Name Speaks; Gospel; Which is also tagged as a Gospel On-line Ministry for Souls Winning...
Pfizer is in talks to supply the US government with another 100 million doses of the company’s coronavirus vaccine, CEO Albert Bourla said Monday.
That would add to the 100 million doses Pfizer plans to deliver by the end of March under an order the Trump administration placed in July, Bourla told CNN.
But the two sides are still haggling over when Pfizer would deliver the second round of doses, according to Bourla. The Manhattan-based drugmaker could provide most of them in the third quarter of next year, but the feds want them to arrive in the second quarter, he said.
“We are working very collaboratively with them to make sure that we can find ways to produce more or allocate the doses in the second quarter as well,” Bourla told CNN. “But we haven’t signed this agreement yet.”
Bourla didn’t mention any financial terms of the pending deal, but the government agreed to pay about $2 billion for the first 100 million doses of the highly effective vaccine from Pfizer and its German partner, BioNTech.
That will be enough to inoculate 50 million people against the deadly COVID-19 bug because the vaccine is administered in two doses.
Last week, President Trump signed an executive order giving Americans “first priority” for the coronavirus vaccine and said he’d invoke the Defense Production Act, if necessary.
The US Department of Health and Human Services did not immediately respond to a request for comment Monday.
Bourla’s comments came as health officials administered the first Pfizer vaccine in the country on Monday. Health-care workers and nursing home residents are among the first in line to get the shots after the Food and Drug Administration cleared them for emergency use on Friday.
Pfizer shares climbed as much as 1.3 percent to $41.66 in early trading Monday.